U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C4H4O6.Fe
Molecular Weight 203.916
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERROUS TARTRATE

SMILES

[Fe++].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O

InChI

InChIKey=OHZCFWMJMWFNFP-ZVGUSBNCSA-L
InChI=1S/C4H6O6.Fe/c5-1(3(7)8)2(6)4(9)10;/h1-2,5-6H,(H,7,8)(H,9,10);/q;+2/p-2/t1-,2-;/m1./s1

HIDE SMILES / InChI
Molecular Formula Fe
Molecular Weight 55.845
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C4H4O6
Molecular Weight 148.071
Charge -2
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3541174 | https://books.google.ru/books?id=7mxyBgAAQBAJ&pg=PA13&lpg=PA13&dq=%22ferrous+iodide%22+anemia&source=bl&ots=ZGyFhUiJZ4&sig=IZOhRVaGmlwX7GcqgoE6rnCsCa4&hl=ru&sa=X&ved=0ahUKEwjYu7PCyYHUAhWiQpoKHR6cCfcQ6AEIUjAJ#v=onepage&q=%22ferrous%20iodide%22&f=false

There is no information about biological and pharmacological application of Iron(II) fluoride (also known as ferrous fluoride). It is known, that this substance is used to catalyze some organic reactions.

Originator

Approval Year

1921
1468
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Not Provided
511
Unknown

Approved Use

Unknown
Palliative
Not Provided
511
Unknown

Approved Use

Unknown
Primary
Approved
8583
Ferro Sanol Duodenal

Approved Use

Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
Curative
Approved
8583
RADIOGARDASE

Approved Use

Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination.

Launch Date

2003
PubMed

PubMed

TitleDatePubMed
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example.
2017-07-05
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle.
2017-05-01
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes.
2017-03-13
Synthesis of phosphabenzenes by an iron-catalyzed [2+2+2] cycloaddition reaction of diynes with phosphaalkynes.
2015-06-22
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
2014
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows.
2013-07
Tolerability of different oral iron supplements: a systematic review.
2013-04
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis.
2011-06-10
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia.
2010-12
Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study.
2009-11-15
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice.
2009
Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.
2007
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe.
1997-10
[Historical notes on the therapy of depression].
1986-11-22
[FERROUS ASPARTATE IN THERAPY].
1964-01-01
Clinical appraisal of drugs with special reference to a new chelate hematinic.
1957-07-11
[Ferrous lactate as an oral iron preparation for therapeutic use].
1954-11-27
THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA.
1937-07
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS.
1932-11-11
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A.
1932-09-30
FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS.
1932-07-01
Patents

Patents

CN105565963
37
US20020127665
37
US2009028810
37
US20150202224
37
US2877253
37
US3091626
37
US5534268
37
US6407138
37
US8080520
37
US8802114
37

Sample Use Guides

In Vivo Use Guide
Adults should usually take one capsule a day. In cases of pronounced iron deficiency, adults can be given a dosage 2 to 3 times higher at the beginning of therapy. A daily dose of more than 5 mg Fe2+/kg body weight should in-well founded exceptional cases not be exceeded.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:36:08 GMT 2025
Edited
by admin
on Mon Mar 31 18:36:08 GMT 2025
Record UNII
ZRW631PTZD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FERRUM TARTARICUM
HPUS  
Preferred Name English
FERROUS TARTRATE
MART.   WHO-DD  
Common Name English
FERROUS TARTRATE [MART.]
Common Name English
Ferrous tartrate [WHO-DD]
Common Name English
IRON(II) TARTRATE
Systematic Name English
TARTARIC ACID, IRON(2+) SALT (1:1)
Common Name English
FERRUM TARTARICUM [HPUS]
Common Name English
IRON TARTRATE (FE(C4H4O6))
Common Name English
BUTANEDIOIC ACID, 2,3-DIHYDROXY- (2R,3R)-, IRON(2+) SALT (1:1)
Common Name English
Classification Tree Code System Code
WHO-ATC B03AA08
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
WHO-VATC QB03AA08
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
Code System Code Type Description
PUBCHEM
6451676
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
PRIMARY
FDA UNII
ZRW631PTZD
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
PRIMARY
DRUG BANK
DB13639
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
PRIMARY
EPA CompTox
DTXSID301019697
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
PRIMARY
SMS_ID
100000078494
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
PRIMARY
ChEMBL
CHEMBL3707386
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
PRIMARY
CAS
2944-65-2
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
PRIMARY
DRUG CENTRAL
4545
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
PRIMARY
ECHA (EC/EINECS)
220-950-1
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
PRIMARY
EVMPD
SUB13879MIG
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
PRIMARY
WIKIPEDIA
Ferrous tartrate
Created by admin on Mon Mar 31 18:36:08 GMT 2025 , Edited by admin on Mon Mar 31 18:36:08 GMT 2025
PRIMARY
Related Record Type Details
Structure of Tartaric Acid
PARENT -> SALT/SOLVATE
Structure of FERROUS CATION
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of FERROUS CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966